N-[1-[4-[3-[amino-(1-chloro-1-methylidene-cyclopropyl)methyl]-3-chloropropyl]-1-methyl-5-oxo-1-azacyclooct-2-en-1-yl]-2-keto-1-methyl-ethylidene]-2-methyl-1,3-diazaspiro[2.5]octane-4-carboxamide

CAS No.：

Cat. No.: SC251290

Available on Request

Price on Request

Bulk Inquiry

Product Name :N-[1-[4-[3-[amino-(1-chloro-1-methylidene-cyclopropyl)methyl]-3-chloropropyl]-1-methyl-5-oxo-1-azacyclooct-2-en-1-yl]-2-keto-1-methyl-ethylidene]-2-methyl-1,3-diazaspiro[2.5]octane-4-carboxamide

Cat. No.: :SC251290

Purity / Specification :—

CAS No. :2024569-19-3

MDL No. :—

Molecular Formula :C₂₀H₂₈ClN₇O₂

LogP :—

Molecular Weight :433.94

TPSA :—

Category :CRO / Contract Research

HSN Code :—

SMILES Code :Cc1nc(N)c(CCC2CCN(C(=O)[C@H](C)NC(=O)c3ccnn3C)CC2)c(Cl)n1

Melting Point :—

InChI Key : :—

Boiling Point :No data available

Application Note

AI Generated

Generated by AI. Verify before use in regulatory documents.

Lipinski & ADMET Properties

Computational estimate

Lipinski Rule of 5

✗ FAIL

MW ≤ 500 Da✓ 433.9 Da

LogP ≤ 5— N/A

HBD ≤ 5— N/A

HBA ≤ 10— N/A

Max 1 violation allowed for oral bioavailability.

Drug-likeness Score

76/100

Good drug-like profile

Predicted LogP

N/A

CNS Permeability

Clark model · J Pharm Sci, 1999

TPSA data required

Requires experimental confirmation.

⚠ These are computational estimates based on Lipinski & Veber physicochemical rules. They are not validated ADMET predictions and must not be used for clinical, regulatory, or safety decisions. For research use only.